RxDoctor Payments Data

Brett Sperry, MD

Advanced Heart Failure and Transplant Cardiology · Kansas City, MONPI 1982920534

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $197,588 of the $313,931 with a category attached, or 62.9%. 11 manufacturers reported payments, led by Pfizer at 56.7% of the total. 2025 is the largest year on record at $82,823, 2.7 times the $30,775 reported in 2019. Among advanced heart failure and transplant cardiology clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$313,931in general payments, 2019–2025

Across 227 payments — averaging $1382.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$178K
  • Alnylam Pharmaceuticals Inc.$85K
  • AstraZeneca$35K
  • Novartis$10K
  • Astrazeneca UK Limited$4K
  • Abbott$1K
  • plus $650 from 5 others
$349,092in research payments, 2019–2025

Across 46 payments — averaging $7588.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$127K
  • AstraZeneca$83K
  • Eidos Therapeutics, Inc.$61K
  • Alnylam Pharmaceuticals Inc.$30K
  • Ionis Pharmaceuticals, Inc.$25K
  • Astrazeneca UK Limited$23K

What the payments were for

  • Consulting fees$91,31829%
  • Speaking & faculty fees$197,58863%
  • Travel & lodging$20,0296%
  • Food & beverage$4,9202%
  • Education$750%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$313,931 in reported general payments places this provider in the 90th percentile of 26 advanced heart failure and transplant cardiology providers in Missouri.

See all advanced heart failure and transplant cardiology providers in Missouri

Medicare billing

Part B allowed, 2024
$125,173
Medicare patients
919
Services billed
2,154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis611$14,123,619
EliquisApixaban238$228,395
JardianceEmpagliflozin150$160,089
EntrestoSacubitril/Valsartan143$144,704
FarxigaDapagliflozin Propanediol99$96,506
XareltoRivaroxaban46$52,019
Repatha SureclickEvolocumab25$27,807
OzempicSemaglutide20$25,732
MounjaroTirzepatide13$16,086
Eplerenone98$7,602
Sirolimus22$7,274
Tacrolimus57$6,205
Torsemide212$5,358
MultaqDronedarone Hcl14$5,294
Valganciclovir Hcl14$4,392

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$177,892$14,352,014849 claims
NovartisEntresto$9,587$144,704143 claims
AstraZenecaFarxiga$35,007$96,50699 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 26 advanced heart failure and transplant cardiology providers in Missouri.

Other advanced heart failure and transplant cardiology in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →